Clobazam

Introduction Overview

Generic Name

clobazam

Brand Name

Sympazan

Dosage Form

Oral film containing 5 mg, 10 mg, or 20 mg of clobazam

Drug Class

Benzodiazepine anticonvulsants

Pharmacokinetics

Absorption:
Clobazam administered as the Sympazan oral film is designed for rapid dissolution on the tongue, facilitating prompt absorption through the oral mucosa and gastrointestinal tract. After administration, clobazam exhibits good bioavailability, with peak plasma concentrations typically reached within 1 to 4 hours. The oral film dosage form may provide a more convenient route for pediatric and adult patients who experience difficulty swallowing traditional tablets. The absorption process can be influenced by food intake, although clobazam can be taken with or without food without significant impact on overall absorption. Clinical studies have demonstrated consistent systemic absorption across populations when dosed as an oral film.

Distribution:
Clobazam has a large volume of distribution, indicating extensive tissue penetration. It is approximately 70-80% bound to plasma proteins, primarily albumin, which aids in its steady plasma concentrations during chronic dosing. The lipophilic nature of clobazam allows it to cross the blood-brain barrier effectively, reaching therapeutic concentrations in the central nervous system to exert anticonvulsant effects. Distribution also includes crossing the placental barrier, posing considerations in pregnant patients. The drug is detectable in breast milk, warranting caution during lactation.

Metabolism:
Clobazam is extensively metabolized in the liver primarily via cytochrome P450 enzymes, notably CYP3A4 and CYP2C19 isoforms. The major active metabolite is N-desmethylclobazam, which contributes significantly to the anticonvulsant activity and has a longer half-life than the parent compound. The hepatic metabolism involves N-demethylation and subsequent glucuronidation pathways before renal excretion. Variability in CYP2C19 activity, due to genetic polymorphisms, can affect the plasma levels of both clobazam and its active metabolite, influencing therapeutic response and risk of adverse effects. Clinically, patients with reduced CYP2C19 function may require dose adjustments.

Elimination:
Elimination of clobazam and its metabolites occurs primarily through renal excretion, with a smaller proportion eliminated via feces. The elimination half-life of clobazam ranges from 36 to 42 hours, while its active metabolite N-desmethylclobazam has a considerably longer half-life averaging 60 to 80 hours, allowing once or twice-daily dosing regimens. Kidney function plays an important role in clearance, though no significant accumulation has been observed in mild to moderate renal impairment; however, caution and monitoring are recommended in severe renal dysfunction. Steady-state plasma levels are generally achieved within 1 to 2 weeks of consistent dosing.

Dosage Forms

Available Dosage Forms:
Sympazan is supplied as an oral film designed to be placed on top of the tongue for dissolution. The available strengths are 5 mg, 10 mg, and 20 mg of clobazam per oral film.

Dosages for Adults and Adolescents:
Initial dosing for Lennox-Gastaut syndrome in patients weighing over 30 kg starts at 10 mg orally once daily, with titration up to 40 mg daily split into two divided doses by day 14. For those 30 kg or less, initial dosing is 5 mg daily with titration up to 20 mg daily, also administered in divided doses. Geriatric patients start at 5 mg daily regardless of weight, with slower titration and maximum doses adjusted accordingly. Once daily doses above 5 mg are recommended to be divided to optimize tolerability and efficacy.

Specific Patient Populations:
Pediatric patients aged 2 years and older receive dosing based on weight as described above, with careful weekly titration increments of 5 to 10 mg to prevent adverse effects and withdrawal symptoms. Use in children under 2 years of age is not approved due to insufficient safety and efficacy data. Dosage adjustments are necessary in patients with hepatic impairment due to altered metabolism, and caution is warranted in patients with respiratory or psychiatric comorbidities. Tapering is recommended when discontinuing therapy to minimize seizure risk and withdrawal syndrome. No dose adjustments for renal impairment are clearly defined but monitoring is advised.

Mechanism Of Action

Clobazam, the active compound in Sympazan, is a 1,5-benzodiazepine that exerts its anticonvulsant effect primarily through modulation of gamma-aminobutyric acid (GABA) neurotransmission. It binds preferentially to specific sites on the GABA_A receptor complex, distinct from 1,4-benzodiazepines, enhancing the affinity of GABA for its receptor. This allosteric modulation results in increased frequency of chloride channel openings, leading to hyperpolarization of neuronal membranes and subsequent inhibition of neuronal excitability.

At a cellular level, clobazam-induced potentiation of GABA-mediated inhibitory synaptic transmission suppresses the propagation of epileptiform activity within the central nervous system. This enhanced inhibitory neurotransmission reduces seizure frequency and intensity, which is particularly crucial in the context of Lennox-Gastaut syndrome, characterized by multifocal seizure types and cognitive impairment.

Biochemically, clobazam’s unique binding profile offers a differentiated pharmacological effect with potentially fewer sedative properties compared to classical benzodiazepines, which may translate into improved tolerability. The active metabolite, N-desmethylclobazam, similarly interacts with GABA_A receptors and sustains anticonvulsant activity, further contributing to the clinical efficacy of therapy.

Clinical studies have demonstrated that Sympazan’s efficacy in reducing seizures in Lennox-Gastaut syndrome stems from these molecular interactions. Compared to other benzodiazepines such as clonazepam or diazepam, clobazam’s unique structure may confer a longer duration of action and a distinct side effect profile, making it advantageous for adjunctive therapy in resistant epilepsies. Ongoing research continues to evaluate the receptor subtype specificity and pharmacodynamic nuances that underpin its therapeutic benefits.

Pharmacological Actions

Acts as a positive allosteric modulator of GABA_A receptors enhancing inhibitory neurotransmission
Exerts anticonvulsant effects by reducing neuronal excitability through membrane hyperpolarization
Produces anxiolytic and muscle relaxant properties attributed to benzodiazepine receptor binding
Has a longer half-life active metabolite (N-desmethylclobazam) contributing to sustained efficacy
Displays less sedative and cognitive impairment relative to classical 1,4-benzodiazepines at therapeutic doses
Effectively decreases seizure frequency in patients with Lennox-Gastaut syndrome
Produces dose-dependent central nervous system depression necessitating monitoring
Possesses potential for tolerance, dependence, and withdrawal phenomena following prolonged use
May influence hormonal contraceptive efficacy by enzyme induction
Provides adjunctive therapy for treatment-resistant epileptic syndromes

Therapeutic Or Clinical Uses

Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients aged 2 years and older
Management of refractory epilepsy where multiple antiepileptic drugs have failed
Reduction in frequency and severity of multiple seizure types including tonic, atonic, and atypical absence seizures
Potential off-label use in other generalized seizure disorders based on clinician discretion
Improvement in behavioral and developmental comorbidities associated with Lennox-Gastaut syndrome
Alternative benzodiazepine therapy for patients intolerant to other agents
Facilitation of seizure control to enhance quality of life in pediatric and adult epilepsy patients
Adjunct for preventing seizure exacerbations during medication tapering protocols
Clinical use within multidisciplinary epilepsy management programs for severe epileptic encephalopathies
Utilized with caution during pregnancy when benefits outweigh risks, given potential neonatal withdrawal

Side Or Adverse Effects

Drowsiness or persistent tiredness impairing daily activities
Slurred speech reflecting central nervous system depression
Agitation, anger, or aggressive behavior including irritability
Constipation potentially related to autonomic effects
Painful urination indicating possible urinary retention or infection
Fever, cough, and respiratory difficulties raising concern for infections or drug-induced respiratory depression
Excessive drooling (sialorrhea) impacting comfort and hygiene
Risk of respiratory depression, particularly when combined with opioids or alcohol
Severe allergic reactions including hives, swelling, and difficulty breathing
Serious dermatologic reactions such as blistering rash requiring immediate medical attention
Mood and behavioral changes encompassing anxiety, panic attacks, depression, and potential suicidal ideation
Balance and coordination problems increasing fall risk especially in elderly patients
Withdrawal symptoms including seizures, hallucinations, confusion, and hyperactivity upon abrupt discontinuation
Potential for physical dependence and overdose if misused
Cognitive impairment or memory disturbances with chronic use

Precautions

Use cautiously in patients with respiratory insufficiency or chronic lung disease due to risk of respiratory depression
Monitor for mood alterations and suicidal ideation especially in patients with history of depression or psychiatric disorders
Avoid abrupt discontinuation; taper dose gradually to prevent withdrawal seizures and neuropsychiatric symptoms
Assess liver and kidney function prior to initiation and during treatment to detect impaired metabolism or elimination
Administer cautiously in individuals with history of substance abuse due to risk of dependence
Advise women of childbearing potential on reliable contraception as clobazam can reduce hormonal contraceptive efficacy
Use during pregnancy only if benefits outweigh potential risks, owing to danger of neonatal withdrawal and teratogenicity
Carefully monitor breastfed infants for sedation and feeding difficulties when mother is on therapy
Avoid concomitant use with other CNS depressants unless clinically necessary, under strict supervision
Educate patients regarding potential impairment of mental and physical abilities; caution when driving or operating machinery
Ensure storage in a secure place to prevent misuse or accidental ingestion by children or others
Regularly evaluate seizure control and side effect profile to optimize dosing
Be vigilant for signs of allergic or severe skin reactions
Consider genetic testing for CYP2C19 variants in cases of unusual response or toxicity
Continued monitoring required even after dose adjustments, especially in pediatric and geriatric populations

Warnings

Sympazan can cause serious respiratory depression, especially when combined with opioids, alcohol, or other CNS depressants
There is a significant risk of misuse, addiction, overdose, or death; keep the medication secure from others
Abrupt cessation after long-term therapy may lead to increased seizures, life-threatening withdrawal symptoms, and neuropsychiatric complications
Severe skin reactions have been reported; discontinue immediately if skin pain, rash with blistering, or peeling occurs
Patients may develop suicidal thoughts or behaviors; monitor mental status closely and report sudden mood changes
Do not share medication with others; illegal distribution or misuse can have fatal consequences
Use during pregnancy can harm the fetus with potential for life-threatening neonatal withdrawal syndrome
Efficacy of hormonal contraceptives may be diminished for at least 28 days after last dose; recommend backup contraception
Drowsiness and dizziness caused by Sympazan may last longer in the elderly, increasing risk of falls or accidents
Patients should avoid alcohol intake to prevent fatal CNS depression
Usage is contraindicated in children under 2 years old due to safety concerns
Overdose can be fatal and requires immediate medical intervention
Patients with a history of drug or alcohol addiction require careful monitoring due to increased risk of dependence
Parenteral administration is not approved; use only the oral film formulation as prescribed
Use caution and adjust doses in patients with hepatic or renal impairment to reduce toxicity risk

Contraindication

Known hypersensitivity or allergy to clobazam or benzodiazepine derivatives
Patients with severe respiratory insufficiency or sleep apnea syndrome due to risk of respiratory depression
Use concomitantly with other CNS depressants without medical supervision
History of acute narrow-angle glaucoma as benzodiazepines may precipitate attacks
Patients younger than 2 years old due to lack of safety and efficacy data
Severe hepatic impairment without careful dose adjustment
Patients with myasthenia gravis owing to muscle relaxant properties
Use in pregnancy unless no safer alternatives and potential benefits outweigh risks
Known hypersensitivity to any of the excipients contained in the oral film formulation
Individuals with untreated severe depression or suicidal ideation unless under psychiatric care
Severe renal impairment cases without adequate monitoring
Patients undergoing abrupt withdrawal from chronic benzodiazepine therapy without gradual taper
Concurrent use with potent CYP3A4 inhibitors or inducers without dose management
History of benzodiazepine misuse or addiction if risk evaluation is negative
Contraindicated in patients with sleep-related breathing disorders aggravated by CNS depressants

Drug Interactions

Concurrent use with opioid analgesics increases risk of profound sedation, respiratory depression, coma, and death
Alcohol consumption potentiates CNS depressant effects leading to fatal respiratory impairment
Other central nervous system depressants such as barbiturates, sedative hypnotics, muscle relaxants, and antipsychotics increase sedation and respiratory risks
Enzyme-inducing antiepileptic drugs (e.g., carbamazepine, phenytoin) may decrease clobazam plasma levels, reducing efficacy
CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase clobazam and metabolite concentrations, raising toxicity risk
Pharmacodynamic interaction with other benzodiazepines causing additive sedation and respiratory depression
Hormonal contraceptives efficacy is reduced; backup non-hormonal contraception is required during and for 28 days post-therapy
Valproic acid co-administration may alter clobazam metabolism necessitating dose adjustments
Drugs that inhibit CYP2C19 (e.g., omeprazole) can increase active metabolite levels, leading to increased sedation
Interaction with herbal supplements like St. John's Wort may induce metabolism, decreasing clobazam effectiveness
Theophylline and aminophylline may antagonize benzodiazepine effects
Drugs affecting gastric pH have minimal impact but should be monitored
Cautious use with digoxin, lithium, or other narrow therapeutic index drugs due to altered CNS sensitivity
Interactions with certain antidepressants (SSRIs, MAOIs) may enhance CNS depressant effects
Antacids and multivitamins have no significant interaction but should be taken spaced from dosing

Preparations Of The Drug

Sympazan oral film strips available in 5 mg, 10 mg, and 20 mg strengths
Each oral film strip is designed for sublingual or buccal administration with rapid dissolution
Packaged with child-resistant materials to prevent accidental ingestion
Stored at controlled room temperature, protected from moisture and heat
Available in blister packaging or bottles depending on market formulations
Intended for once or twice-daily dosing based on prescribed regimen
No parenteral or injectable formulation available commercially
Formulated without alcohol to reduce systemic absorption variability
Compatible with other antiepileptic therapies for adjunctive use
Manufactured in compliance with Good Manufacturing Practices (GMP)
Formulation includes inactive ingredients such as flavoring agents to improve palatability
Designed to reduce swallowing difficulties common in pediatric and elderly patients
Supplied with comprehensive patient instructions to ensure proper administration
Prescription-only medication requiring medical supervision
Discard unused or expired films according to local pharmaceutical waste regulations